Aligos Therapeutics (ALGS) SEC Filings: History & Chart

Aligos Therapeutics, Inc.(ALGS)

Biotechnology · South San Francisco, CA

$5.40-0.14 (-2.53%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.

South San Francisco, CA

82 employees

www.aligos.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lawrence Blatt

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 15, 2026	Sep 15, 2026	View filing
S-8	Aug 6, 2026	Aug 6, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
8-K	Jun 26, 2026	Jun 26, 2026	View filing
SC 13D	Jun 24, 2026	Jun 24, 2026	View filing
SC 13G	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
DEFA14A	Apr 29, 2026	Apr 29, 2026	View filing
ARS	Apr 29, 2026	Apr 29, 2026	View filing
DEF 14A	Apr 29, 2026	Apr 29, 2026	View filing
8-K	Apr 21, 2026	Apr 21, 2026	View filing
8-K	Apr 14, 2026	Apr 14, 2026	View filing
4	Mar 11, 2026	Mar 11, 2026	View filing
4	Mar 11, 2026	Mar 11, 2026	View filing
4	Mar 11, 2026	Mar 11, 2026	View filing
4	Mar 11, 2026	Mar 11, 2026	View filing
S-8	Mar 5, 2026	Mar 5, 2026	View filing
10-K	Mar 5, 2026	Mar 5, 2026	View filing
8-K	Mar 5, 2026	Mar 5, 2026	View filing
3	Feb 19, 2026	Feb 19, 2026	View filing
SC 13G/A	Feb 17, 2026	Feb 17, 2026	View filing

SEC Filings

Recent Filings